Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment

　　1.Core Conclusion:No Simple Answer

　　Whether anagrelide worsens myelofibrosis is a common concern for patients with essential thrombocythemia(ET).Current medical evidence cannot simply answer"yes"or"no."​While some studies observed increased bone marrow reticulin or fibrosis transformation in ET patients treated with anagrelide,these observational findings are confounded by the natural disease course,patient characteristics,and treatment choices,preventing a definitive causal link.

　　2.Review of Clinical Evidence

　　Several studies provide insights but have limitations:

　　A study in ET and polycythemia vera(PV)found increased bone marrow reticulin indices after anagrelide,suggesting it may not halt the disease's fibrotic progression.

　　Long-term follow-up observed myelofibrosis transformation in some ET patients,but confounding factors preclude direct attribution to the drug.

　　A large retrospective study comparing ET outcomes before and after anagrelide approval noted differences in myelofibrosis-free survival,but authors explicitly stated that retrospective design cannot confirm anagrelide as the cause of survival decline or fibrosis increase.

　　3.Inherent Risk of Disease Progression

　　ET is a myeloproliferative neoplasm(MPN)with a natural history that includes potential progression to myelofibrosis.A long-term study found increased fibrosis risk in patients with longer anagrelide use,but this likely reflects the disease's natural evolution over time rather than sole drug toxicity.

　　4.Therapeutic Role and Monitoring

　　Anagrelide's primary role is to lower platelet counts,not to treat or prevent myelofibrosis.For patients on long-term therapy,monitoring is key:

　　Parameters:Regular blood counts,spleen size,anemia status,and disease-related symptoms(e.g.,night sweats,bone pain,weight loss).

　　Bone marrow assessment:Long-term studies emphasize the importance of periodic bone marrow examination to detect fibrotic changes.

　　Decision-making:Any detected change requires comprehensive evaluation by a physician to distinguish disease progression from drug effect and guide treatment adjustment.